Effective Prognostic Marker Identified for Ovarian Cancer
By LabMedica International staff writers Posted on 20 Aug 2014 |
Image: Histopathology of high-grade serous ovarian carcinoma (Photo courtesy of Dr. Ed Uthman, MD).
High-grade serous ovarian carcinoma (HG- SOC) is the most prevalent of epithelial ovarian cancers and remains poorly understood due to a lack of biomarkers identified for clinical use, for diagnosis, or for prognosis of patient survival rates.
The application of bioinformatics analysis on cancer genomics data has enabled the identification genes whose mutation status could be used for prognosis and development of personalized treatment for HG-SOC, which is the most lethal ovarian cancers, with only 30% patients surviving more than five years after diagnosis.
Scientists at the Agency for Science, Technology and Research (A*STAR; Singapore) analyzed data from 334 HG-SOC patients logged in the Cancer Genome Atlas (TCGA; Bethesda, MD, USA). The sequences were generated based on either Illumina (San Diego, CA, USA) or ABI SOLID sequencing technologies (Applied Biosystems; Carlsbad, CA, USA).
The team identified the gene, Checkpoint Kinase 2 (CHEK2), as an effective prognostic marker of patient survival. HG-SOC patients with mutations in this gene succumbed to the disease within five years of diagnosis, possibly because CHEK2 mutations were associated with poor response to existing cancer therapies. Mortality after diagnosis currently remains high, as patients receive similar treatment options of chemotherapy and radiotherapy despite the diverse nature of tumor cells within tumors and across different tumor samples. With these findings, personalized medicine for ovarian cancer could be developed, with targeted treatment that would be optimized for subgroups of patients.
Sir David Philip Lane, FRS, FRSE FRCPath, the chief scientist at A*STAR, said, “These findings show how the various research institutes at A*STAR offer their expertise in developing new approaches to examine different aspects of the same disease that have not been successfully studied before, such as ovarian cancer. The diverse capabilities and knowledge of our scientists allows us to investigate diseases holistically, from diagnosis to treatment.” The study was published on July 15, 2014, in the journal Cell Cycle.
Related Links:
Agency for Science, Technology and Research
The Cancer Genome Atlas
Illumina
The application of bioinformatics analysis on cancer genomics data has enabled the identification genes whose mutation status could be used for prognosis and development of personalized treatment for HG-SOC, which is the most lethal ovarian cancers, with only 30% patients surviving more than five years after diagnosis.
Scientists at the Agency for Science, Technology and Research (A*STAR; Singapore) analyzed data from 334 HG-SOC patients logged in the Cancer Genome Atlas (TCGA; Bethesda, MD, USA). The sequences were generated based on either Illumina (San Diego, CA, USA) or ABI SOLID sequencing technologies (Applied Biosystems; Carlsbad, CA, USA).
The team identified the gene, Checkpoint Kinase 2 (CHEK2), as an effective prognostic marker of patient survival. HG-SOC patients with mutations in this gene succumbed to the disease within five years of diagnosis, possibly because CHEK2 mutations were associated with poor response to existing cancer therapies. Mortality after diagnosis currently remains high, as patients receive similar treatment options of chemotherapy and radiotherapy despite the diverse nature of tumor cells within tumors and across different tumor samples. With these findings, personalized medicine for ovarian cancer could be developed, with targeted treatment that would be optimized for subgroups of patients.
Sir David Philip Lane, FRS, FRSE FRCPath, the chief scientist at A*STAR, said, “These findings show how the various research institutes at A*STAR offer their expertise in developing new approaches to examine different aspects of the same disease that have not been successfully studied before, such as ovarian cancer. The diverse capabilities and knowledge of our scientists allows us to investigate diseases holistically, from diagnosis to treatment.” The study was published on July 15, 2014, in the journal Cell Cycle.
Related Links:
Agency for Science, Technology and Research
The Cancer Genome Atlas
Illumina
Latest Molecular Diagnostics News
- Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
- New DNA Origami Technique to Advance Disease Diagnosis
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans